# BMS Acquires Orbital Therapeutics for $1.5 Billion to Secure Circular RNA Cell Therapy

> ma · REPORTED · 2025-06-20

Bristol Myers Squibb acquired Orbital Therapeutics for $1.5 billion, gaining OTX-201, a circular RNA therapy designed to induce patients' own cells to produce anti-CD19 CAR-type constructs for B cell-driven autoimmune disorders, deepening BMS's cell therapy portfolio.

- Company: Bristol Myers Squibb
- Sector: biotech
- Primary source: https://www.biospace.com/business/the-7-most-impactful-m-a-deals-of-2025

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.